Trends in tolvaptan prescription and the association between hypernatremia and aging in tolvaptan-treated patients in Japan: Real-world data mining using Japanese databases.

IF 0.9 4区医学 Q4 PHARMACOLOGY & PHARMACY

International journal of clinical pharmacology and therapeutics Pub Date : 2023-01-01 DOI:10.5414/CP204307

Takaya Uno, Kouichi Hosomi, Satoshi Yokoyama, Kazuyoshi Kawabata

{"title":"Trends in tolvaptan prescription and the association between hypernatremia and aging in tolvaptan-treated patients in Japan: Real-world data mining using Japanese databases.","authors":"Takaya Uno, Kouichi Hosomi, Satoshi Yokoyama, Kazuyoshi Kawabata","doi":"10.5414/CP204307","DOIUrl":null,"url":null,"abstract":"Objective: To identify the trends in tolvaptan prescription and the association between aging and tolvaptan-induced hypernatremia.Materials and methods: A health insurance claims database and a spontaneous adverse drug reaction database were used.Results: Of all patients who had been prescribed tolvaptan, the proportion of patients aged 60 - 79 years and ≥ 80 years was consistent at ~ 40%. Moreover, the prescription frequency of tolvaptan increased over time for patients in the same age groups. The adjusted reporting odds ratio of tolvaptan-induced hypernatremia was 5.54 (95% confidence interval, 3.31 - 9.25) in patients aged ≥ 60 years from among all patients and 2.09 (95% confidence interval, 1.59 - 2.75) in those aged ≥ 80 years from among those aged ≥ 60 years.Conclusion: It may be necessary to be aware of hypernatremia in elderly patients who are expected to have increased prescriptions of tolvaptan.","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":"61 1","pages":"33-36"},"PeriodicalIF":0.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of clinical pharmacology and therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5414/CP204307","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To identify the trends in tolvaptan prescription and the association between aging and tolvaptan-induced hypernatremia.

Materials and methods: A health insurance claims database and a spontaneous adverse drug reaction database were used.

Results: Of all patients who had been prescribed tolvaptan, the proportion of patients aged 60 - 79 years and ≥ 80 years was consistent at ~ 40%. Moreover, the prescription frequency of tolvaptan increased over time for patients in the same age groups. The adjusted reporting odds ratio of tolvaptan-induced hypernatremia was 5.54 (95% confidence interval, 3.31 - 9.25) in patients aged ≥ 60 years from among all patients and 2.09 (95% confidence interval, 1.59 - 2.75) in those aged ≥ 80 years from among those aged ≥ 60 years.

Conclusion: It may be necessary to be aware of hypernatremia in elderly patients who are expected to have increased prescriptions of tolvaptan.

查看原文本刊更多论文

日本托伐普坦治疗患者的处方趋势和高钠血症与衰老之间的关系:使用日本数据库的真实世界数据挖掘。

目的:了解托伐普坦处方变化趋势及衰老与托伐普坦致高钠血症的关系。材料和方法:使用健康保险索赔数据库和自发药物不良反应数据库。结果:在所有处方托伐普坦的患者中，60 - 79岁和≥80岁的患者比例一致，为~ 40%。此外，在同一年龄组的患者中，托伐普坦的处方频率随时间而增加。在所有患者中，年龄≥60岁的患者中，托伐普坦诱导的高钠血症的校正报告优势比为5.54(95%可信区间，3.31 - 9.25)，年龄≥80岁的患者中，年龄≥60岁的患者中，tolvaptan诱导的高钠血症的校正报告优势比为2.09(95%可信区间，1.59 - 2.75)。结论:有可能增加托伐普坦处方的老年患者有必要注意高钠血症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International journal of clinical pharmacology and therapeutics 医学-药学

CiteScore

1.70

自引率

12.50%

发文量

116

审稿时长

4-8 weeks

期刊介绍： The International Journal of Clinical Pharmacology and Therapeutics appears monthly and publishes manuscripts containing original material with emphasis on the following topics: Clinical trials, Pharmacoepidemiology - Pharmacovigilance, Pharmacodynamics, Drug disposition and Pharmacokinetics, Quality assurance, Pharmacogenetics, Biotechnological drugs such as cytokines and recombinant antibiotics. Case reports on adverse reactions are also of interest.